Interface risk assessment from design controls and hazard analysis — interoperability cybersecurity assessment extends this to include protocol-layer vulnerability analysis and cross-system trust boundary evaluation.
FDA section V.A.3 requires explicit assessment of whether added security controls beneath interoperability protocols are needed, documentation of controls for all connected external systems, and confirmation that cybersecurity controls do not restrict authorized user access to device data.
Assessment of added controls beneath common protocols (especially BLE and WiFi), coverage of all external interfaces in the threat model, and protection against protocol-layer vulnerabilities — missing BLE security controls beneath the protocol layer is a common finding.
Maps to
FDA Cybersecurity: §V.A.3 Interoperability Considerations
Requirement text
FDA's Premarket Cybersecurity Guidance (current edition February 3, 2026) recommends that manufacturers assess and document the cybersecurity risks and controls associated with interoperability capabilities of medical devices. Interoperable medical devices have the ability to exchange and use information through an electronic interface with another medical or nonmedical product, system, or device. Manufacturers should consider appropriate cybersecurity controls associated with interoperability — including interfaces with other medical devices, healthcare infrastructure, and general-purpose computing platforms — and document these considerations as recommended throughout the guidance.
Why this clause exists
Interoperability creates cybersecurity risk surfaces that do not exist in isolated, standalone devices. A device that exchanges data with other medical devices, Electronic Medical Records systems, or general-purpose computing platforms inherits the attack surface of those connected systems and creates a potential pathway for adversarial traversal across the broader healthcare IT environment. FDA guidance V.A.3 addresses interoperability as a distinct risk category because the security properties of common interoperability protocols (Bluetooth, Bluetooth Low Energy, network protocols) cannot be assumed — vulnerabilities in Bluetooth Low Energy, for example, may not be addressed by the device manufacturer even if the underlying protocol stack has a documented security flaw. The guidance emphasizes that cybersecurity controls should be a means to enable the safe exchange of information, not a barrier to interoperability — the expected result is that properly implemented cybersecurity controls allow interoperability to function safely rather than restrict it. The explicit protection that cybersecurity controls should not prohibit users from accessing their device data reflects FDA's patient-rights policy.
What changed
FDA's September 2023 final guidance (updated February 2026) section V.A.3 establishes interoperability cybersecurity assessment as a distinct required element of premarket submissions, going beyond the general 'secure the interface' guidance in the 2014 draft. The specific requirement to assess whether added security controls beneath common protocols (including Bluetooth Low Energy) are needed addresses post-2014 protocol-layer vulnerability findings. The explicit protection of user data access rights in the context of cybersecurity controls is a new policy statement.
Common gaps (what we see in audits)
- Bluetooth and BLE interfaces assessed at protocol level only without added security controls — Devices using Bluetooth Low Energy for medical device programming or data exchange frequently rely on BLE's native security without assessing whether additional controls beneath the protocol layer are needed to address potential BLE protocol vulnerabilities. FDA guidance V.A.3 recommends that manufacturers assess whether added security controls beneath BLE and similar protocols are needed to maintain safety and effectiveness if vulnerabilities in those protocols are discovered post-market.